What is ERNA's relative strength rating?

ERNA ranks at the 90th percentile over 1 month, 5th percentile over 3 months, 20th percentile over 6 months, 5th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is ERNA in?

ERNA is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is ERNA in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). ERNA benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is ERNA?

ERNA currently shows a 20-day average daily range (ADR%) of 11.1%, a 90-day beta versus the S&P 500 of 1.81. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does ERNA have a seasonal pattern?

TickerStance computes ERNA's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what ERNA has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did ERNA last report earnings?

ERNA most recently filed a 10-Q covering FY26 Q2 with the SEC on 2026-08-06. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.

Ernexa Therapeutics Inc. Common Stock (ERNA)

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Ernexa Therapeutics Inc. Common Stock (ERNA) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 29. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 11.1%, relative volume 0.53×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month5pctile

6 month20pctile

1 year5pctile

Classic5IBD pctile

LDR3leadership

0 of 5 lenses lit · avg RS pctile 7

✓ADR%11.1%✓A/DA!RVOL0.53×!$ Vol$4M

COMPUTED · AS OF 2026-08-24

Pattern read

ERNA is in a stage 4 downtrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -3.9% / -65.7%.

Pure factual computation. Not a recommendation. See stage analysis.

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

Evidence · 1 of 3

Receipts behind the read

1 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

90

3m

5

6m

20

1y

5

LDR

—

StageWeinstein stage analysis

Stage 4 · Decline✓

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · ERNA

Does the business back the chart?

SEC EDGAR · last filing 10-Q · FY26 Q2 · period end 2026-06-30

43

Fundamentals Growth Rank

How does growth rank vs. the universe?

vs. 4,480 ranked stocks · Sector rank 47

View fundamental leadership map

Average

Earnings

Are losses narrowing?

Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.

Loss widening

−$4.92—

24 Q3

$3.91—

24 Q4

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
ERNA
5RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

AKBAAkebia Therapeutics, Inc.20 PROKProKidney Corp. Class A Ordinary Shares20 NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares19 PBHPrestige Consumer Healthcare Inc.20

§ Seasonality

10y · since 2022

Best monthMay on averageavg +42.92% · 75% win · n 4

Worst monthNov on averageavg -30.95% · 25% win · n 4

ERNA monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	ERNA Jan avg: 18.12% median: 15.19% win: 75% σ: 25.62% n: 4 2022-10-18 → 2026-07-31	ERNA Feb avg: -30.67% median: -19.74% win: 0% σ: 31.26% n: 4 2022-10-18 → 2026-07-31	ERNA Mar avg: -7.37% median: -20.94% win: 25% σ: 42.61% n: 4 2022-10-18 → 2026-07-31	ERNA Apr avg: -12.77% median: -20.56% win: 25% σ: 20.03% n: 4 2022-10-18 → 2026-07-31	ERNA May avg: 42.92% median: 6.33% win: 75% σ: 97.00% n: 4 2022-10-18 → 2026-07-31	ERNA Jun avg: -19.09% median: -20.39% win: 25% σ: 25.23% n: 4 2022-10-18 → 2026-07-31	ERNA Jul avg: -8.79% median: -3.54% win: 25% σ: 30.58% n: 4 2022-10-18 → 2026-07-31	ERNA Aug avg: -10.90% median: -11.91% win: 33% σ: 12.76% n: 3 2022-10-18 → 2026-07-31 (current)	ERNA Sep avg: -23.88% median: -17.67% win: 0% σ: 17.19% n: 3 2022-10-18 → 2026-07-31	ERNA Oct avg: 1.41% median: -15.37% win: 50% σ: 50.29% n: 4 2022-10-18 → 2026-07-31	ERNA Nov avg: -30.95% median: -32.18% win: 25% σ: 25.79% n: 4 2022-10-18 → 2026-07-31	ERNA Dec avg: 13.99% median: -6.32% win: 25% σ: 58.26% n: 4 2022-10-18 → 2026-07-31

Public attention · ERNA

Is the crowd watching?

45/ 100 · vs its own 90-day norm▲ 5 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Reference

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float691Kshares

Shares out1.2Mshares

Market cap$5.9MNano Cap

FAQ

Frequently asked questions

What is ERNA's relative strength rating?: ERNA ranks at the 90th percentile over 1 month, 5th percentile over 3 months, 20th percentile over 6 months, 5th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is ERNA in?: ERNA is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is ERNA in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). ERNA benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is ERNA?: ERNA currently shows a 20-day average daily range (ADR%) of 11.1%, a 90-day beta versus the S&P 500 of 1.81. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does ERNA have a seasonal pattern?: TickerStance computes ERNA's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what ERNA has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

Ernexa Therapeutics Inc. Common Stock (ERNA) — Stance & relative strength

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

§ Seasonality

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?

§ Seasonality

Ernexa Therapeutics Inc. Common Stock (ERNA) — Stance & relative strength

ERNA is not confirmed as a leader. 5 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Pattern read

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Are losses narrowing?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

Is revenue confirming?

Are margins expanding?

Share count: tailwind or headwind?